Abstract | AIM: METHODS: Two groups of 12 white male patients with essential hypertension were treated with candoxatril at 25 mg every 12 h (group 1) or at 200 mg every 12 h (group 2) for 5 days in double-blind, placebo-controlled, crossover studies. RESULTS: CONCLUSIONS:
|
Authors | A M Richards, G A Wittert, I G Crozier, E A Espiner, T G Yandle, H Ikram, C Frampton |
Journal | Journal of hypertension
(J Hypertens)
Vol. 11
Issue 4
Pg. 407-16
(Apr 1993)
ISSN: 0263-6352 [Print] England |
PMID | 8390508
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Indans
- Propionates
- Angiotensin II
- Atrial Natriuretic Factor
- candoxatril
- Neprilysin
|
Topics |
- Adult
- Angiotensin II
(administration & dosage, blood)
- Atrial Natriuretic Factor
(administration & dosage, blood)
- Blood Pressure
(drug effects)
- Double-Blind Method
- Heart Rate
(drug effects)
- Humans
- Hypertension
(blood, drug therapy, physiopathology)
- Indans
(pharmacology)
- Kidney
(drug effects)
- Male
- Middle Aged
- Natriuresis
(drug effects)
- Neprilysin
(antagonists & inhibitors)
- Propionates
(pharmacology)
- Time Factors
|